Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meineng is a brand name for compound glycyrrhizin, a combination drug containing glycyrrhizin (glycyrrhizic acid), glycine, and DL-methionine. It is primarily used for the treatment of chronic liver disease to improve liver function and for various inflammatory skin conditions such as eczema, dermatitis, and alopecia areata. Glycyrrhizin, the active component derived from licorice root, possesses anti-inflammatory, anti-allergic, and hepatoprotective properties. Glycine and methionine are included to mitigate potential side effects of glycyrrhizin, such as pseudoaldosteronism (sodium retention and potassium loss). It is widely used in East Asia, particularly China and Japan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound glycyrrhizin.